Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 10, 2010, Pages 4669-4674

  Roha, Jason D ^a   Sawh Martinez, Rajendra ^a   Brennan, Matthew P ^a   Jay, Steven M ^a   Devine, Lesley ^a   Rao, Deepak A ^a   Yi, Tai ^a   Mirensky, Tamar L ^a   Nalbandian, Ani ^a   Udelsman, Brooks ^a   Hibino, Narutoshi ^a   Shinoka, Toshiharu ^a   Saltzman, W Mark ^a   Snyder, Edward ^a   Kyriakides, Themis R ^a   Pober, Jordan S ^a   Breuer, Christopher K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; Monocyte chemoattractant protein 1; Neovascularization; Tissue engineering

Indexed keywords

CAPROLACTAM; CYTOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYGLYCOLIC ACID; POLYLACTIC ACID; RNA; SCAFFOLD PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; BLOOD VESSEL GRAFT; BONE MARROW; BONE MARROW CELL; CELL DIFFERENTIATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICRO-COMPUTED TOMOGRAPHY; MONOCYTE; MONONUCLEAR CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SCID MOUSE; STEM CELL; TISSUE ENGINEERING; VEIN GRAFT;

ANIMALS; ANTIGENS, CD31; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; BLOOD VESSELS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINE CCL2; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, SCID; MICROSCOPY, ELECTRON, SCANNING; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77949531670     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0911465107     Document Type: Article

References (44)

1. Kannan RY, Salacinski HJ, Butler PE, Hamilton G, Seifalian AM (2005) Current status of prosthetic bypass grafts: A review. J Biomed Mater Res, Part B 74:570-581.
2. Fernandez G, et al. (1989) Prevalence of reoperation for pathway obstruction after Fontan operation. Ann Thorac Surg 48:654-659.
3. Alexi-Meskishvili V, et al. (2000) Optimal conduit size for extracardiac Fontan operation. Eur J Cardiothorac Surg 18:690-695.
4. Hibino N, Shin'oka T, Matsumura G, Ikada Y, Kurosawa H (2005) The tissue-engineered vascular graft using bone marrow without culture. J Thorac Cardiovasc Surg 129:1064-1070.
5. Matsumura G, et al. (2006) Evaluation of tissue-engineered vascular autografts. Tissue Eng 12:3075-3083.
6. Isomatsu Y, et al. (2006) Extracardiac total cavopulmonary connection using a tissue-engineered graft. J Thorac Cardiovasc Surg 126:1958-1962.
7. MatsumuraG, Hibino N, Ikada Y, Kurosawa H, Shin'oka T (2003) Successful application of tissue engineered vascular autografts: Clinical experience. Biomaterials 24:2303-2308.
8. Shin'oka T, et al. (2005) Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg 129: 1330-1338.
9. Brennan MP, et al. (2008) Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model. Ann Surg 248: 370-377.
10. Matsumura G, Miyagawa-Tomita S, Shin'oka T, Ikada Y, Kurosawa H (2003) First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation 108:1729-1734.
11. Roh JD, et al. (2008) Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. Biomaterials 29:1454-1463.
12. Voskuil M, et al. (2003) Modulation of collateral artery growth in a porcine hind limb ligation model using MCP-1. Am J Physiol Heart Circ Physiol 284:H422-H428.
13. van Royen N, et al. (2003) Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 92:218-225.
14. Ito WD, et al. (1997) Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 80:829-837.
15. Scholz D, et al. (2000) Ultrastructural and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Arch 436:257-270.
16. Ziegelhoeffer T, et al. (2004) Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 94:230-238.
17. Zentilin L, et al. (2006) Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 107:3546-3554.
18. Murry CE, et al. (2004) Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428:664-668.
19. Balsam LB, et al. (2004) Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428:668-673.
20. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL (2002) Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297:2256-2259.
21. Kinnaird T, et al. (2004) Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109:1543-1549.
22. Gnecchi M, et al. (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11:367-368.
23. O'Neill TJ, 4th, Wamhoff BR, Owens GK, Skalak TC (2005) Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. Circ Res 97:1027-1035.
24. Kinnaird T, et al. (2004) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94:678-685.
25. Uemura R, Xu M, Ahmad N, Ashraf M (2006) Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98: 1414-1421.
26. Terada N, et al. (2002) Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416:542-545.
27. Ying QL, Nichols J, Evans EP, Smith AG (2002) Changing potency by spontaneous fusion. Nature 416:545-548.
28. Alvarez-Dolado M, et al. (2003) Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425:968-973.
29. Nygren JM, et al. (2004) Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10:494-501.
30. Shum-Tim D, et al. (1999) Tissue engineering of autologous aorta using a new biodegradable polymer. Ann Thorac Surg 68:2298-2304, discussion 2305.
31. Watanabe M, et al. (2001) Tissue-engineered vascular autograft: Inferior vena cava replacement in a dog model. Tissue Eng 7:429-439.
32. Arras M, et al. (1998) Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 101:40-50.
33. Heil M, et al. (2002) Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 283:H2411-H2419.
34. Bergmann CE, et al. (2006) Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J Leukocyte Biol 80:59-65.
35. Heil M, et al. (2004) Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res 94: 671-677.
36. Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, Shapiro SD, Kolattukudy PE (2000) Contribution of monocytes/macrophages to compensatory neovascularization: The drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res 87:378-384.
37. Rehman J, Li J, Orschell CM, March KL (2003) Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107:1164-1169.
38. Grunewald M, et al. (2006) VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 124:175-189.
39. Alon T, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028.
40. Asahara T, et al. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228.
41. Zouggari Y, et al. (2009) Regulatory T cells modulate postischemic neovascularization. Circulation 120:1415-1425.
42. Van Weel V, et al. (2007) Natural killer cells and CD4+ T-cells modulate collateral artery development. Arterioscler Thromb Vasc Biol 27:2310-2318.
43. Roh JD, et al. (2006) Gylcolmethacrylate is superior to methylmethacrylate for histologic evaluation of biodegradable polymer scaffolds used for vascular tissue engineering. J Histotechnol 29:245-252.
44. Jay SM, Shepherd BR, Bertram JP, Pober JS, Saltzman WM (2008) Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation. FASEB J 22:2949-2956